Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Seamless Phase II/III combination study through response adaptive randomization.

Lin Wang1, Lu Cui

  • 1Biostatistics and Programming, Sanofi Aventis, Bridgewater, New Jersey 08807, USA. lin.wang2@sanofi-aventis.com

Journal of Biopharmaceutical Statistics
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Synergistic effect of thermotherapy in combination with chemotherapy on lung tumor A549 cells growth through activation of c-Jun N-terminal kinase and inhibition of heat shock protein70 expression].

Wei sheng yan jiu = Journal of hygiene research·2008
Same author

Joint effects of arsenic and cadmium on plant growth and metal bioaccumulation: a potential Cd-hyperaccumulator and As-excluder Bidens pilosa L.

Journal of hazardous materials·2008
Same author

Impact of systemic blood pressure on the relationship between intraocular pressure and blood flow in the optic nerve head of nonhuman primates.

Investigative ophthalmology & visual science·2008
Same author

Diagnosis and treatment of pancreatic somatostatinoma: a case report.

Chinese medical journal·2008
Same author

Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma.

Cancer letters·2008
Same author

Evaluation of solvent tolerance of microorganisms by microcalorimetry.

Chemosphere·2008
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study introduces a seamless clinical trial design for drug development. It combines Phase II dose finding and Phase III confirmation, improving efficiency and reliability while controlling errors.

Area of Science:

  • Clinical Trials
  • Pharmaceutical Research
  • Biostatistics

Background:

  • Traditional drug development uses separate Phase II (dose finding) and Phase III (confirmation) studies.
  • This sequential approach is inefficient, costly, and provides limited data from Phase II.
  • There is a need for more integrated and reliable clinical trial methodologies.

Purpose of the Study:

  • To propose a seamless, adaptive clinical trial design.
  • To combine dose identification and effectiveness confirmation into a single study.
  • To enhance the efficiency and reliability of drug development processes.

Main Methods:

  • Developed a seamless design integrating Phase II and Phase III trials.
  • Utilized adaptive patient allocation for dynamic dose selection.

Related Experiment Videos

  • Investigated methods for controlling the type I error rate.

    • Main Results:

    • Simulations demonstrated successful control of the type I error rate.
    • The proposed seamless design significantly improved study efficiency.
    • Reliability of the drug development process was greatly enhanced compared to traditional methods.

    Conclusions:

    • The seamless adaptive design offers a superior alternative to traditional sequential trials.
    • This integrated approach optimizes resource allocation and accelerates drug development.
    • The method provides a robust framework for both dose finding and confirmation.